Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer

Next Previous
Trial Profile

A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary)
  • Indications Carcinoma; Endometrial cancer; Sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SIENDO; SIENDO / ENGOT-EN5
  • Sponsors Karyopharm Therapeutics

    • Most Recent Events

    • 08 Jan 2024 According to a Karyopharm Therapeutics media release, Top-Line Data Readouts Expected in 2H 2024 and 2025.Further Updates Planned to be Presented in 2024
    • 06 Nov 2023 Results updated long-term safety and efficacy from a pre-specified exploratory subgroup analysis presented in a Karyopharm Therapeutics media release.
    • 06 Nov 2023 According to a Karyopharm Therapeutics media release, the company looking forward to additional data in the first half of 2025 from the company's ongoing pivotal Phase 3 trial that may support U.S. and global regulatory filings.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top